Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-4
- Development stage
- Phase 3
- Lead developer
- University Health Network
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**MET-4** is an investigational, orally administered live microbial consortium developed by NuBiyota as a cultivated and standardized alternative to fecal microbiota transplantation. It comprises 30 individually cultured, lyophilized intestinal bacterial species originally isolated from a healthy donor and formulated in capsules. MET-4 is intended to restore or reshape gut microbial diversity and function, promote gastrointestinal microbial colonization and epithelial-barrier integrity, and potentially enhance systemic and antitumor immune responses to immune checkpoint inhibitors. It has been studied with immune checkpoint inhibitors in advanced solid tumors and with chemoradiotherapy in human papillomavirus-related locoregionally advanced oropharyngeal squamous cell carcinoma. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/microbial-ecosystem-therapeutics-4))
- Other names
- Microbial Ecosystem Therapeutic 4Microbial Ecosystem Therapeutics 4microbial ecosystem therapeutics-4
Beyond the preview
Go deeper on MET-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-4.